Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: A study in Japan

Annals of Neurology

Volumn 44, Issue 1, 1998, Pages 17-26

  Kanai, M ^a   Matsubara, E ^a   Isoe, K ^d   Urakami, K ^d   Nakashima, K ^d   Arai, H ^e   Sasaki, H ^e   Abe, K ^e   Iwatsubo, T ^f   Kosaka, T ^f   Watanabe, M ^a   Tomidokoro, Y ^a   Shizuka, M ^a   Mizushima, K ^c   Nakamura, T ^b   Igeta, Y ^a   Ikeda, Y ^a   Amari, M ^c   Kawarabayashi, T ^a   Ishiguro, K ^b   Harigaya, Y ^a   Wakabayashi, K ^a   Okamoto, K ^a   Hirai, S ^g   Shoji, M ^a,h   more..

^a GUNMA UNIVERSITY   (Japan)

^b MAEBASHI RED CROSS HOSPITAL   (Japan)

^c Geriatrics Research Institute and Hospital   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g TOKYO METROPOLITAN NEUROLOGICAL HOSPITAL   (Japan)

^h GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ADOLESCENT; ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEX CHARACTERISTICS; TAU PROTEINS;

EID: 14444269228     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440108     Document Type: Article

References (51)

1. Glenner GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984; 120: 885-890
2. Shoji M, Golde TE, Ghiso J, et al. Production of the Alzheimer amyloid β protein by normal proteolytic processing. Science 1992;258:126-129
3. Haass C, Schlossmacher MG, Hung AY, et al. Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 1992;359:322-325
4. Iizuka T, Shoji M, Kawarabayashi T, et al. Intracellular generation of amyloid β-protein from amyloid β-protein precursor fragment by direct cleavage with β- and γ-secretase. Biochem Biophys Res Commun 1996;218:238-242
5. Lee VMY, Balin BJ, Otvos L, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal tau. Science 1991;251:675-678
6. Roher AE, Lowenson JD, Clarke S, et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993;268:3072-3083
7. Iwatsubo T, Odaka A, Suzuki N, et al. Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: evidence that an initially deposited species is Aβ42(43). Neuron 1994;13:45-53
8. Gravina SA, Ho L, Eckman CB, et al. Amyloid βprotein (Aβ) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at Aβ40 or Aβ42(43). J Biol Chem 1995;270:7013-7016
9. Iizuka T, Shoji M, Harigaya Y, et al. Amyloid β-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid. Brain Res 1995;702:275-278
10. Harigaya Y, Shoji M, Kawarabayashi T, et al. Modified amyloid β protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease. Biochem Biophys Res Commun 1995;211:1015-1022
11. Castano EM, Prelli F, Soto C, et al. The length of amyloid-β in hereditary cerebral hemorrhage with amyloidosis, Dutch type. Implications for the role of amyloid-β1-42 in Alzheimer's disease. J Biol Chem 1996;271:32185-32191
12. Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733-736
13. Mann DMA. The pathological association between Down syndrome and Alzheimer disease. Mech Aging Dev 1988;43:99-136
14. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991;349:704-706
15. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995;375:754-760
16. Rogaev EI, Sherrington R, Roageva EA, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376:775-778
17. Ikeda M, Sharma V, Sumi SM, et al. The clinical phenotype of two missense mutations in the presenilin 1 gene in Japanese patients. Ann Neurol 1996;40:912-917
18. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870
19. Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/ 1-40 ratio in vitro and in vivo. Neuron 1996;17:1005-1013
20. N3(pE), in senile plaques. Neuron 1995;14:457-466
21. Iwatsubo T, Saido TC, Mann DMA, et al. Full-length amyloid-β(1-42(43)) and amino-terminally modified and truncated amyloid-β42(43) deposit in diffuse plaques. Am J Pathol 1996; 149:1823-1830
22. Citron M, Oltersdorf T, Haass C, et al. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 1992;360:672-674
23. 717) mutants. Science 1994;264:1336-1340
24. Citron M, Westaway D, Xia W, et al. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67-72
25. Duff K, Eckman C, Zehr C, et al. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1. Nature 1996; 383:710-713
26. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessmenr of Alzheimer's disease. Neurology 1991;41:479-486
27. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of T proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61:1828-1834
28. Mori H, Hosoda K, Matsubara E, et al. Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 1995;186: 181-183
29. Arai H, Terajima M, Miura M, et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann Neurol 1995;38:649-652
30. Blomberg M, Jensen M, Basun H, et al. Increasing cerebrospinal fluid tau levels in a subgroup of Alzheimer patients with apolipoprotein E allele ε4 during 14 months follow-up. Neurosci Lett 1996;214:163-166
31. Galasko D, Clark C, Chang L, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997;48:632-635
32. Riemenschneider M, Buch K, Schmolke M, et al. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett 1996;212:209-211
33. Tato RE, Frank A, Hernanz A. Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 1995;59:280-283
34. 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648
35. Aoki M, Abe K, Oda N, et al. A presenilin-1 mutation in a Japanese family with Alzheimer's disease and distinctive abnormalities on cranial MRI. Neurology 1997;48:1118-1120
36. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944
37. Rinne JO, Lee MS, Thompson PD, Marsden CD. Corticobasal degeneration. A clinical study of 36 cases. Brain 1994;117: 1183-1196
38. Steele JC, Richardson JC, and Olszewski J. Progressive supranuclear palsy. Arch Neurol 1964;10:333-359
39. Kosaka K. Diffuse neurofibrillary tangles with calcification: a new presenile dementia. J Neurol Neurosurg Psychiatry 1994; 57:594-596
40. Mitsuyama Y. Presenile dementia with motor neuron disease in Japan: clinico-pathological review of 26 cases. J Neurol Neurosurg Psychiatry 1984;47:953-959
41. Lopez OL, Larumbe MR, Becker JT, et al. Reliability of NINCDS-AIREN clinical criteria for the diagnosis of vascular dementia. Neurology 1994;44:1240-1245
42. McKeith JG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-1124
43. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198
44. Reisberg B, Ferris SH, Anand R, et al. Functional staging of dementia of the Alzheimer type. Ann NY Acad Sci 1984;435: 481-483
45. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577
46. Nakamura T, Shoji M, Harigaya Y, et al. Amyloid β protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 1994;36:903-911
47. Ghersi-Egea JF, Gorevic PD, Ghiso J, et al. Fate of cerebrospinal fluid-borne amyloid β-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 1996;67:880-883
48. Tokuda T, Fukushima T, Ikeda S, et al. Plasma levels of amyloid β proteins Aβ1-40 and Aβ1-42(43) are elevated in Down's syndrome. Ann Neurol 1997;41:271-273
49. Kawarabayashi T, Shoji M, Sato M, et al. Accumulation of β-amyloid fibrils in pancreas of transgenic mice. Neurobiol Aging 1996;17:215-222
50. Isoe K, Urakami K, Shimomura T, et al. Tau proteins in cerebrospinal fluid from patients with Alzheimer's disease: a longitudinal study. Demenria 1996;7:173-176
51. Hock C, Golombowski S, Naser W, Müller-Spahn F. Increased levels of τ protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Ann Neurol 1995;37:414-415